APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Antigen Gp39

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global T Cell Antigen Gp39 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025181 pages

Choose your research edition.

Industry ResearchT Cell Antigen Gp39 Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Antigen Gp39 Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal T Cell Antigen Gp39 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Antigen Gp39 Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Antigen Gp39 Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global T Cell Antigen Gp39 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of T Cell Antigen Gp39 include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T Cell Antigen Gp39 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T Cell Antigen Gp39 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T Cell Antigen Gp39 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T Cell Antigen Gp39 market size, projected growth trends, production technologies, key applications, and end-use industries.

T Cell Antigen Gp39 Segment by Company

Biogen, Inc.

XL-protein GmbH

Targovax AS

MedImmune, LLC

Juno Therapeutics Inc.

ImmuNext, Inc.

eTheRNA Immunotherapies NV

Bristol-Myers Squibb Company

T Cell Antigen Gp39 Segment by Type

ECI-006

Hepatitis B Vaccine

ISF-35

INX-021

Others

T Cell Antigen Gp39 Segment by Application

Graft Versus Host Disease

Panceratic Cancer

Breast Cancer

Bladder Cancer

Others

T Cell Antigen Gp39 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Antigen Gp39 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Antigen Gp39 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Antigen Gp39.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T Cell Antigen Gp39 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of T Cell Antigen Gp39 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of T Cell Antigen Gp39 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. T Cell Antigen Gp39 Industry Trends Table 2. T Cell Antigen Gp39 Industry Drivers Table 3. T Cell Antigen Gp39 Industry Opportunities and Challenges Table 4. T Cell Antigen Gp39 Industry Restraints Table 5. Global T Cell Antigen Gp39 Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global T Cell Antigen Gp39 Revenue Market Share by Manufacturers (2021-2026) Table 7. Global T Cell Antigen Gp39 Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global T Cell Antigen Gp39 Sales Market Share by Manufacturers Table 9. Global T Cell Antigen Gp39 Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global T Cell Antigen Gp39 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global T Cell Antigen Gp39 Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global T Cell Antigen Gp39 Manufacturers, Product Type & Application Table 13. Global T Cell Antigen Gp39 Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global T Cell Antigen Gp39 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ECI-006 Table 17. Major Manufacturers of Hepatitis B Vaccine Table 18. Major Manufacturers of ISF-35 Table 19. Major Manufacturers of INX-021 Table 20. Major Manufacturers of Others Table 21. Global T Cell Antigen Gp39 Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 23. Global T Cell Antigen Gp39 Sales by Type (2027-2032) & (K Units) Table 24. Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2026) Table 25. Global T Cell Antigen Gp39 Sales Market Share by Type (2027-2032) Table 26. Global T Cell Antigen Gp39 Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global T Cell Antigen Gp39 Revenue by Type (2021-2026) & (K Units) Table 28. Global T Cell Antigen Gp39 Revenue by Type (2027-2032) & (K Units) Table 29. Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2026) Table 30. Global T Cell Antigen Gp39 Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Graft Versus Host Disease Table 32. Major Manufacturers of Panceratic Cancer Table 33. Major Manufacturers of Breast Cancer Table 34. Major Manufacturers of Bladder Cancer Table 35. Major Manufacturers of Others Table 36. Global T Cell Antigen Gp39 Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 38. Global T Cell Antigen Gp39 Sales by Application (2027-2032) & (K Units) Table 39. Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2026) Table 40. Global T Cell Antigen Gp39 Sales Market Share by Application (2027-2032) Table 41. Global T Cell Antigen Gp39 Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global T Cell Antigen Gp39 Revenue by Application (2021-2026) & (K Units) Table 43. Global T Cell Antigen Gp39 Revenue by Application (2027-2032) & (K Units) Table 44. Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2026) Table 45. Global T Cell Antigen Gp39 Revenue Market Share by Application (2027-2032) Table 46. Global T Cell Antigen Gp39 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global T Cell Antigen Gp39 Sales by Region (2021-2026) & (K Units) Table 48. Global T Cell Antigen Gp39 Sales Market Share by Region (2021-2026) Table 49. Global T Cell Antigen Gp39 Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global T Cell Antigen Gp39 Sales Forecasted Market Share by Region (2027-2032) Table 51. North America T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 53. North America T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units) Table 54. Europe T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 56. Europe T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units) Table 63. Global T Cell Antigen Gp39 Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global T Cell Antigen Gp39 Revenue by Region (2021-2026) & (US$ Million) Table 65. Global T Cell Antigen Gp39 Revenue by Region (2027-2032) & (US$ Million) Table 66. Global T Cell Antigen Gp39 Revenue Market Share by Region (2021-2026) Table 67. Global T Cell Antigen Gp39 Revenue Market Share by Region (2027-2032) Table 68. Biogen, Inc. Company Information Table 69. Biogen, Inc. Business Overview Table 70. Biogen, Inc. T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Biogen, Inc. T Cell Antigen Gp39 Product Portfolio Table 72. Biogen, Inc. Recent Development Table 73. XL-protein GmbH Company Information Table 74. XL-protein GmbH Business Overview Table 75. XL-protein GmbH T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. XL-protein GmbH T Cell Antigen Gp39 Product Portfolio Table 77. XL-protein GmbH Recent Development Table 78. Targovax AS Company Information Table 79. Targovax AS Business Overview Table 80. Targovax AS T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Targovax AS T Cell Antigen Gp39 Product Portfolio Table 82. Targovax AS Recent Development Table 83. MedImmune, LLC Company Information Table 84. MedImmune, LLC Business Overview Table 85. MedImmune, LLC T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. MedImmune, LLC T Cell Antigen Gp39 Product Portfolio Table 87. MedImmune, LLC Recent Development Table 88. Juno Therapeutics Inc. Company Information Table 89. Juno Therapeutics Inc. Business Overview Table 90. Juno Therapeutics Inc. T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio Table 92. Juno Therapeutics Inc. Recent Development Table 93. ImmuNext, Inc. Company Information Table 94. ImmuNext, Inc. Business Overview Table 95. ImmuNext, Inc. T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio Table 97. ImmuNext, Inc. Recent Development Table 98. eTheRNA Immunotherapies NV Company Information Table 99. eTheRNA Immunotherapies NV Business Overview Table 100. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio Table 102. eTheRNA Immunotherapies NV Recent Development Table 103. Bristol-Myers Squibb Company Company Information Table 104. Bristol-Myers Squibb Company Business Overview Table 105. Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio Table 107. Bristol-Myers Squibb Company Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. T Cell Antigen Gp39 Distributors List Table 111. T Cell Antigen Gp39 Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. T Cell Antigen Gp39 Product Image Figure 2. Global T Cell Antigen Gp39 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Antigen Gp39 Market Size (2021-2032) & (US$ Million) Figure 4. Global T Cell Antigen Gp39 Sales (2021-2032) & (K Units) Figure 5. Global T Cell Antigen Gp39 Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 T Cell Antigen Gp39 Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ECI-006 Image Figure 9. Hepatitis B Vaccine Image Figure 10. ISF-35 Image Figure 11. INX-021 Image Figure 12. Others Image Figure 13. Global T Cell Antigen Gp39 Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global T Cell Antigen Gp39 Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2032) Figure 16. Global T Cell Antigen Gp39 Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global T Cell Antigen Gp39 Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2032) Figure 19. Graft Versus Host Disease Image Figure 20. Panceratic Cancer Image Figure 21. Breast Cancer Image Figure 22. Bladder Cancer Image Figure 23. Others Image Figure 24. Global T Cell Antigen Gp39 Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global T Cell Antigen Gp39 Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2032) Figure 27. Global T Cell Antigen Gp39 Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global T Cell Antigen Gp39 Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2032) Figure 30. North America T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America T Cell Antigen Gp39 Sales Market Share by Country (2021-2032) Figure 32. U.S. T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe T Cell Antigen Gp39 Sales Market Share by Country (2021-2032) Figure 37. Germany T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific T Cell Antigen Gp39 Sales Market Share by Country (2021-2032) Figure 44. China T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa T Cell Antigen Gp39 Sales Market Share by Country (2021-2032) Figure 52. Brazil T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile T Cell Antigen Gp39 Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global T Cell Antigen Gp39 Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global T Cell Antigen Gp39 Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America T Cell Antigen Gp39 Revenue (2021-2032) & (US$ Million) Figure 63. North America T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe T Cell Antigen Gp39 Revenue (2021-2032) & (US$ Million) Figure 65. Europe T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific T Cell Antigen Gp39 Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa T Cell Antigen Gp39 Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. T Cell Antigen Gp39 Value Chain Figure 71. Manufacturing Cost Structure Figure 72. T Cell Antigen Gp39 Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • ECI-006
  • Hepatitis B Vaccine
  • ISF-35
  • INX-021
  • Others
Applications
  • Graft Versus Host Disease
  • Panceratic Cancer
  • Breast Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Biogen, Inc.
  • XL-protein GmbH
  • Targovax AS
  • MedImmune, LLC
  • Juno Therapeutics Inc.
  • ImmuNext, Inc.
  • eTheRNA Immunotherapies NV
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global T Cell Antigen Gp39 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global T Cell Antigen Gp39 Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global T Cell Antigen Gp39 Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global T Cell Antigen Gp39 Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global T Cell Antigen Gp39 Market Dynamics
  1. 2.1 T Cell Antigen Gp39 Industry Trends
  2. 2.2 T Cell Antigen Gp39 Industry Drivers
  3. 2.3 T Cell Antigen Gp39 Industry Opportunities and Challenges
  4. 2.4 T Cell Antigen Gp39 Industry Restraints
3 T Cell Antigen Gp39 Market by Manufacturers
  1. 3.1 Global T Cell Antigen Gp39 Revenue by Manufacturers (2021-2026)
  2. 3.2 Global T Cell Antigen Gp39 Sales by Manufacturers (2021-2026)
  3. 3.3 Global T Cell Antigen Gp39 Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global T Cell Antigen Gp39 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global T Cell Antigen Gp39 Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global T Cell Antigen Gp39 Manufacturers, Product Type & Application
  7. 3.7 Global T Cell Antigen Gp39 Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global T Cell Antigen Gp39 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 T Cell Antigen Gp39 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 T Cell Antigen Gp39 Tier 1, Tier 2, and Tier 3
4 T Cell Antigen Gp39 Market by Type
  1. 4.1 T Cell Antigen Gp39 Type Introduction
  2. 4.1.1 ECI-006
  3. 4.1.2 Hepatitis B Vaccine
  4. 4.1.3 ISF-35
  5. 4.1.4 INX-021
  6. 4.1.5 Others
  7. 4.2 Global T Cell Antigen Gp39 Sales by Type
  8. 4.2.1 Global T Cell Antigen Gp39 Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global T Cell Antigen Gp39 Sales by Type (2021-2032)
  10. 4.2.3 Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2032)
  11. 4.3 Global T Cell Antigen Gp39 Revenue by Type
  12. 4.3.1 Global T Cell Antigen Gp39 Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global T Cell Antigen Gp39 Revenue by Type (2021-2032)
  14. 4.3.3 Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2032)
5 T Cell Antigen Gp39 Market by Application
  1. 5.1 T Cell Antigen Gp39 Application Introduction
  2. 5.1.1 Graft Versus Host Disease
  3. 5.1.2 Panceratic Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global T Cell Antigen Gp39 Sales by Application
  8. 5.2.1 Global T Cell Antigen Gp39 Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global T Cell Antigen Gp39 Sales by Application (2021-2032)
  10. 5.2.3 Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2032)
  11. 5.3 Global T Cell Antigen Gp39 Revenue by Application
  12. 5.3.1 Global T Cell Antigen Gp39 Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global T Cell Antigen Gp39 Revenue by Application (2021-2032)
  14. 5.3.3 Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2032)
6 Global T Cell Antigen Gp39 Sales by Region
  1. 6.1 Global T Cell Antigen Gp39 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T Cell Antigen Gp39 Sales by Region (2021-2032)
  3. 6.2.1 Global T Cell Antigen Gp39 Sales by Region (2021-2026)
  4. 6.2.2 Global T Cell Antigen Gp39 Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America T Cell Antigen Gp39 Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe T Cell Antigen Gp39 Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific T Cell Antigen Gp39 Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa T Cell Antigen Gp39 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global T Cell Antigen Gp39 Revenue by Region
  1. 7.1 Global T Cell Antigen Gp39 Revenue by Region
  2. 7.1.1 Global T Cell Antigen Gp39 Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global T Cell Antigen Gp39 Revenue by Region (2021-2026)
  4. 7.1.3 Global T Cell Antigen Gp39 Revenue by Region (2027-2032)
  5. 7.1.4 Global T Cell Antigen Gp39 Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America T Cell Antigen Gp39 Revenue (2021-2032)
  8. 7.2.2 North America T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe T Cell Antigen Gp39 Revenue (2021-2032)
  11. 7.3.2 Europe T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific T Cell Antigen Gp39 Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa T Cell Antigen Gp39 Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa T Cell Antigen Gp39 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen, Inc.
  2. 8.1.1 Biogen, Inc. Company Information
  3. 8.1.2 Biogen, Inc. Business Overview
  4. 8.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
  6. 8.1.5 Biogen, Inc. Recent Developments
  7. 8.2 XL-protein GmbH
  8. 8.2.1 XL-protein GmbH Company Information
  9. 8.2.2 XL-protein GmbH Business Overview
  10. 8.2.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
  12. 8.2.5 XL-protein GmbH Recent Developments
  13. 8.3 Targovax AS
  14. 8.3.1 Targovax AS Company Information
  15. 8.3.2 Targovax AS Business Overview
  16. 8.3.3 Targovax AS T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Targovax AS T Cell Antigen Gp39 Product Portfolio
  18. 8.3.5 Targovax AS Recent Developments
  19. 8.4 MedImmune, LLC
  20. 8.4.1 MedImmune, LLC Company Information
  21. 8.4.2 MedImmune, LLC Business Overview
  22. 8.4.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
  24. 8.4.5 MedImmune, LLC Recent Developments
  25. 8.5 Juno Therapeutics Inc.
  26. 8.5.1 Juno Therapeutics Inc. Company Information
  27. 8.5.2 Juno Therapeutics Inc. Business Overview
  28. 8.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
  30. 8.5.5 Juno Therapeutics Inc. Recent Developments
  31. 8.6 ImmuNext, Inc.
  32. 8.6.1 ImmuNext, Inc. Company Information
  33. 8.6.2 ImmuNext, Inc. Business Overview
  34. 8.6.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
  36. 8.6.5 ImmuNext, Inc. Recent Developments
  37. 8.7 eTheRNA Immunotherapies NV
  38. 8.7.1 eTheRNA Immunotherapies NV Company Information
  39. 8.7.2 eTheRNA Immunotherapies NV Business Overview
  40. 8.7.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
  42. 8.7.5 eTheRNA Immunotherapies NV Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T Cell Antigen Gp39 Value Chain Analysis
  2. 9.1.1 T Cell Antigen Gp39 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T Cell Antigen Gp39 Production Mode & Process
  6. 9.2 T Cell Antigen Gp39 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T Cell Antigen Gp39 Distributors
  9. 9.2.3 T Cell Antigen Gp39 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst